Grants per year
Personal profile
Certifications and Licenses
| Medical Oncology | |
| Hematology | |
| Internal Medicine |
Training Experience
| 2004 | Residency, University of Chicago Hospitals |
| 2007 | Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
Education/Academic qualification
MD, University of Pittsburgh
… → 2001
Research interests
- Acute Leukemias
- Anemia
- Aplastic Anemia
- Chronic Leukemias
- Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Diseases
- Targeted Therapies
Fingerprint
Dive into the research topics where Jessica K Altman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Liquid Biopsy to Measure Novel Biomarkers of ImmunoMetabolic Cancer Risk (IMCR)
Thaxton, C. S., Abaza, Y., Altman, J. K., Behdad, A. & Griffith, J. W.
V Foundation for Cancer Research
8/1/22 → 8/1/25
Project: Research project
-
Prot #APTO-CG-806-03: A Phase 1a/b Trial of CG-806 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
1/27/21 → 1/27/24
Project: Research project
-
Advances in the pharmacological management of acute myeloid leukemia in adults
Numan, Y., Abaza, Y., Altman, J. K. & Platanias, L. C., 2022, (Accepted/In press) In: Expert Opinion on Pharmacotherapy.Research output: Contribution to journal › Review article › peer-review
-
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Vasu, S., Altman, J. K., Uy, G. L., Tallman, M. S., Gojo, I., Lozanski, G., Burkard, U., Osswald, A., James, P., Rüter, B. & Blum, W., Mar 2022, In: Haematologica. 107, 3, p. 770-773 4 p.Research output: Contribution to journal › Letter › peer-review
Open Access2 Scopus citations -
Bone marrow–confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia
Mei, Y., Ren, K., Liu, Y., Ma, A., Xia, Z., Han, X., Li, E., Tariq, H., Bao, H., Xie, X., Zou, C., Zhang, D., Li, Z., Dong, L., Verma, A., Lu, X., Abaza, Y., Altman, J. K., Sukhanova, M., Yang, J., & 1 others, Sep 1 2022, In: Journal of Clinical Investigation. 132, 17, e152673.Research output: Contribution to journal › Article › peer-review
Open Access -
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Perl, A. E., Hosono, N., Montesinos, P., Podoltsev, N., Martinelli, G., Panoskaltsis, N., Recher, C., Smith, C. C., Levis, M. J., Strickland, S., Röllig, C., Groß-Langenhoff, M., Chou, W. C., Lee, J. H., Yokoyama, H., Hasabou, N., Lu, Q., Tiu, R. V. & Altman, J. K., May 2022, In: Blood cancer journal. 12, 5, 84.Research output: Contribution to journal › Article › peer-review
Open Access -
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients
Zak, T., Gao, J., Behdad, A., Mehta, J., Altman, J. K., Ji, P., Lu, X. & Sukhanova, M., 2022, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Article › peer-review